Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Links shared publicly online about this topic.
- 1,775total visits
Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.
View full resource at drugs.com
Tags: ADHD, ADHD Medication, Children's Health, FDA, Intuniv, Shire, Pediatric ADHD
Most Recently Shared on September 4, 2009 at 12:32 am By:
FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC
FDA approves guanfacine ER tablets to treat ADHD in children, teens - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on March 2, 2011 at 7:52 pm By:
FDA approves guanfacine ER tablets to treat ADHD in children, teens: FDA approved the use of once-daily gu... http://bit.ly/hRwbtM #adhd
Advertisement
